Abstract
We report a rare case of Candida lambica candidemia in a 56-year-old male with acute myeloid leukemia undergoing intensive chemotherapy. Despite fluconazole prophylaxis, the patient developed persistent febrile neutropenia. Blood cultures grew yeast, later identified as C. lambica via ITS rDNA sequencing. Antifungal susceptibility testing revealed sensitivity to voriconazole and other antifungals resulting in clinical improvement following targeted therapy. This case highlights the growing clinical relevance of rare non-albicans candida species in immunocompromised hosts, the limitations of conventional diagnostics, and the importance of molecular tools and antifungal susceptibility testing in guiding effective treatment.